PurposeTo report the 2-year efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for the treatment of primary open-angle glaucoma (POAG). SettingA single surgical site in China. DesignThis was a prospective, randomized controlled trial. POAG patients were randomly assigned to the penetrating canaloplasty or ab externo canaloplasty group. MethodsThis study enrolled POAG patients who underwent penetrating canaloplasty or ab externo canaloplasty randomly. Surgical success, intraocular pressure (IOP), number of glaucoma medications, and surgical complications were evaluated until 24 months post-operatively. Surgical success was defined as 6 mmHg <= IOP <= 21 mmHg with an IOP reduction >= 20%, which included qualified success (with or without medications) and complete success (without medications). ResultsA total of 52 eyes (45 patients) were randomly assigned to one of two groups: the penetrating canaloplasty group (PCP, n = 26) or the ab externo canaloplasty group (CP, n = 26). The probabilities of qualified success and complete success were 92.3% and 76.9%, respectively, in the PCP group and 64.1% and 52.1%, respectively, in the CP group at 24 months (p = 0.013, p = 0.042, log-rank test). The mean IOP decreased from 30.8 +/- 10.7 and 28.6 +/- 11.8 mmHg to 14.1 +/- 3.3 mmHg in the PCP group and 22.1 +/- 13.6 mmHg in the CP group at year two (p = 0.007). The PCP group also received fewer medications (0.2 +/- 0.5) than did the CP group (0.7 +/- 1.2) at year two (p = 0.038). Post-operative complications were similar, and the most common complications were transient IOP elevation and hyphema in the PCP group (42.3%, 46.2%) and the CP group (38.5%, 23.1%) (p > 0.05). ConclusionsCompared to ab externo canaloplasty, penetrating canaloplasty had a greater surgical success rate and better IOP reduction with a comparable rate of complications.
基金：
Key Research and Development Program
of Zhejiang Province, Grant/Award
Number: 2022C03112; National Key
Research and Development Program
of China, Grant/Award Number:
2020YFC2008200; Program for Zhejiang
Leading Talent of S&T Innovation, Grant/
Award Number: 2021R52012
第一作者机构：[1]Wenzhou Med Univ, Eye Hosp, Natl Clin Res Ctr Ocular Dis, 270 Xue Yuan Xi Rd, Wenzhou 325027, Zhejiang, Peoples R China
通讯作者：
通讯机构：[1]Wenzhou Med Univ, Eye Hosp, Natl Clin Res Ctr Ocular Dis, 270 Xue Yuan Xi Rd, Wenzhou 325027, Zhejiang, Peoples R China[*1]National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, No. 270 Xue Yuan Xi Road, Wenzhou 325027, Zhejiang, China.
推荐引用方式(GB/T 7714)：
Ye Wenqing,Li Jinxing,Zhang Shaodan,et al.Efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for primary open-angle glaucoma: A randomized controlled trial[J].ACTA OPHTHALMOLOGICA.2025,103(1):e58-e65.doi:10.1111/aos.16750.
APA：
Ye, Wenqing,Li, Jinxing,Zhang, Shaodan,Zhu, Shuqing,Xie, Yanqian...&Liang, Yuanbo.(2025).Efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for primary open-angle glaucoma: A randomized controlled trial.ACTA OPHTHALMOLOGICA,103,(1)
MLA：
Ye, Wenqing,et al."Efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for primary open-angle glaucoma: A randomized controlled trial".ACTA OPHTHALMOLOGICA 103..1(2025):e58-e65
